<DOC>
	<DOCNO>NCT00637832</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . Radiolabeled monoclonal antibody , yttrium Y 90 ibritumomab tiuxetan , find cancer cell carry cancer-killing substance without harm normal cell . Giving rituximab together combination chemotherapy yttrium Y 90 ibritumomab tiuxetan may kill cancer cell . PURPOSE : This phase II trial study well give rituximab together combination chemotherapy yttrium Y 90 ibritumomab tiuxetan work treat patient relapse follicular non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Rituximab , Combination Chemotherapy , Yttrium Y 90 Ibritumomab Tiuxetan Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate response rate patient relapse follicular non-Hodgkin lymphoma treat short-duration rituximab combination chemotherapy ( R-chemo ) follow rituximab yttrium Y 90 ibritumomab tiuxetan . Secondary - To evaluate duration response patient treat regimen . - To evaluate quality response order determine conversion rate partial response complete response patient treat regimen . - To evaluate toxicity yttrium Y 90 ibritumomab tiuxetan administer 3 course R-chemo . OUTLINE : This multicenter study . - Chemoimmunotherapy ( R-CHOP R-CVP ) : Patients receive R-CHOP comprise rituximab IV , cyclophosphamide IV , doxorubicin hydrochloride IV , vincristine IV day 1 oral prednisolone day 1-5 . Alternatively , patient already expose prior tolerance dos anthracyclines receive R-CVP comprising rituximab IV , cyclophosphamide IV , vincristine IV day 1 oral prednisolone day 1-5 . Treatment repeat every 3 week 3 course . Patients objective evidence response CT scan &lt; 25 % bone marrow involvement sign bone marrow hypocellularity ( &lt; 15 % ) bone marrow biopsy proceed radioimmunotherapy . - Radioimmunotherapy : Four 6 week completion R-CHOP R-CVP , patient receive rituximab IV follow 4 hour later yttrium Y 90 ibritumomab tiuxetan IV 10 minute . After completion study therapy , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm grade 1 , 2 , 3 follicular nonHodgkin lymphoma Stage II , III , IV disease ( accord Ann Arbor stag system ) CD20positive disease Initial disease bulk ≤ 10 cm In first second relapse prior treatment rituximabcontaining chemotherapy regimen ( Rchemo ) chemotherapy alone Relapse must occur ≥ 6 month completion Rchemo Relapse occur &lt; 6 month completion chemotherapy alone allow Has least one follow symptom require initiation treatment : Nodal mass &gt; 5 cm great diameter B symptom Elevated serum lactate dehydrogenase ( LDH ) β2microglobulin Involvement ≥ 3 nodal site ( diameter &gt; 3 cm ) Symptomatic splenic enlargement Compressive syndrome No primary refractory disease No large pleural peritoneal effusion No CNS disease PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 6 month Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 1,000/mm³ Serum creatinine &lt; 1.5 time upper limit normal ( ULN ) Total bilirubin &lt; 1.5 time ULN AST &lt; 5 time ULN No active obstructive hydronephrosis No evidence active infection require IV antibiotic No advance heart disease serious illness would preclude study evaluation No known HIV infection No human antimouse antibody ( HAMA ) reactivity No known hypersensitivity murine antibody proteins Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month completion study treatment No prior malignancy , except adequately treated skin cancer , cervical cancer situ , cancer patient diseasefree 5 year PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week since prior investigational drug recover No prior radioimmunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
</DOC>